Janux Therapeutics, Inc. (JANX): Price and Financial Metrics

Janux Therapeutics, Inc. (JANX): $40.08

1.92 (-4.57%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add JANX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#199 of 352

in industry

JANX Price/Volume Stats

Current price $40.08 52-week high $65.60
Prev. close $42.00 52-week low $5.65
Day low $40.00 Volume 651,500
Day high $42.75 Avg. volume 793,428
50-day MA $48.98 Dividend yield N/A
200-day MA $23.58 Market Cap 2.08B

JANX Stock Price Chart Interactive Chart >


Janux Therapeutics, Inc. (JANX) Company Bio


Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.


JANX Latest News Stream


Event/Time News Detail
Loading, please wait...

JANX Latest Social Stream


Loading social stream, please wait...

View Full JANX Social Stream

Latest JANX News From Around the Web

Below are the latest news stories about JANUX THERAPEUTICS INC that investors may wish to consider to help them evaluate JANX as an investment opportunity.

An Intrinsic Calculation For Janux Therapeutics, Inc. (NASDAQ:JANX) Suggests It's 44% Undervalued

Key Insights The projected fair value for Janux Therapeutics is US$18.66 based on 2 Stage Free Cash Flow to Equity...

Yahoo | December 27, 2023

Does Janux Therapeutics, Inc. (JANX) Have the Potential to Rally 205.5% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 205.5% in Janux Therapeutics, Inc. (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | December 1, 2023

Wall Street Analysts See a 220.17% Upside in Janux Therapeutics, Inc. (JANX): Can the Stock Really Move This High?

The consensus price target hints at a 220.2% upside potential for Janux Therapeutics, Inc. (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | November 15, 2023

Janux Therapeutics, Inc. (JANX) Loses -34.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Janux Therapeutics, Inc. (JANX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Yahoo | November 10, 2023

Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

SAN DIEGO, November 07, 2023--Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Yahoo | November 7, 2023

Read More 'JANX' Stories Here

JANX Price Returns

1-mo -14.90%
3-mo 3.75%
6-mo 320.57%
1-year 218.85%
3-year 103.66%
5-year N/A
YTD 273.53%
2023 -18.53%
2022 -33.25%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!